Nutr Res Pract.  2016 Aug;10(4):411-417. 10.4162/nrp.2016.10.4.411.

Leptin and uric acid as predictors of metabolic syndrome in jordanian adults

• Obeidat AA
• Ahmad MN
• Haddad FH
• Azzeh FS

• KMID: 2390144
• DOI: http://doi.org/10.4162/nrp.2016.10.4.411

Abstract

BACKGROUND/OBJECTIVES
Metabolic syndrome (MetS) is a set of interrelated metabolic risk factors that increase the risk of cardiovascular morbidity and mortality. Studies regarding the specificity and sensitivity of serum levels of leptin and uric acid as predictors of MetS are limited. The aim of this study was to evaluate the serum levels of leptin and uric acid in terms of their specificity and sensitivity as predictors of MetS in the studied Jordanian group.
SUBJECTS/METHODS
In this cross sectional study, 630 adult subjects (308 men and 322 women) were recruited from the King Hussein Medical Center (Amman, Jordan). The diagnosis of MetS was made according to the 2005 International Diabetes Federation criteria. Receiver operating characteristic curves were used to determine the efficacy of serum levels of leptin and uric acid as predictors of MetS in the studied Jordanian group.
RESULTS
Study results showed that for identification of subjects with MetS risk, area under the curve (AUC) for leptin was 0.721 and 0.683 in men and women, respectively. Serum uric acid levels in men showed no significant association with any MetS risk factors and no significant AUC, while uric acid AUC was 0.706 in women.
CONCLUSION
Serum leptin levels can be useful biomarkers for evaluation of the risk of MetS independent of baseline obesity in both men and women. On the other hand, serum uric acid levels predicted the risk of MetS only in women.

Keyword

Metabolic syndrome; leptin; uric acid

MeSH Terms

Adult*
Area Under Curve
Biomarkers
Diagnosis
Female
Hand
Humans
Leptin*
Male
Mortality
Obesity
Risk Factors
ROC Curve
Sensitivity and Specificity
Uric Acid*
Biomarkers
Leptin
Uric Acid

Figure

• 

  Fig. 1 Receiver operating characteristic curves of leptin and uric acid levels for identifying subjects with MS in men. Leptin (ng/ml) Optimal Cut-Off Point (7.55); AUC (0.721); Sensitivity % (0.72); Specificity % (0.721); P-value (< 0.001). Uric Acid (mg/dl) Optimal Cut-Off Point (6.35); AUC (0.56); Sensitivity % (0.378); Specificity % (0.848); P-value (NS). AUC: Area Under the Curve; NS, Not Significant.

• 

  Fig. 2 Receiver operating characteristic curves of leptin and uric acid levels for identifying subjects with MS in women. Leptin (ng/ml) Optimal Cut-Off Point (21.5); AUC (0.683); Sensitivity % (0.64); Specificity % (0.708); P-value (< 0.001). Uric Acid (mg/dl) Optimal Cut-Off Point (4.35); AUC (0.706); Sensitivity % (0.753); Specificity % (0.597); P-value (< 0.001). AUC: Area Under the Curve

Reference

1. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr. International Diabetes Federation Task Force on Epidemiology and Prevention. Hational Heart, Lung, and Blood Institute. American Heart Association. World Heart Federation. International Atherosclerosis Society. International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009; 120:1640–1645.

2. van Vliet-Ostaptchouk JV, Nuotio ML, Slagter SN, Doiron D, Fischer K, Foco L, Gaye A, Gögele M, Heier M, Hiekkalinna T, Joensuu A, Newby C, Pang C, Partinen E, Reischl E, Schwienbacher C, Tammesoo ML, Swertz MA, Burton P, Ferretti V, Fortier I, Giepmans L, Harris JR, Hillege HL, Holmen J, Jula A, Kootstra-Ros JE, Kvaløy K, Holmen TL, Männistö S, Metspalu A, Midthjell K, Murtagh MJ, Peters A, Pramstaller PP, Saaristo T, Salomaa V, Stolk RP, Uusitupa M, van der Harst P, van der Klauw MM, Waldenberger M, Perola M, Wolffenbuttel BH. The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies. BMC Endocr Disord. 2014; 14:9–22.

3. Gallagher EJ, LeRoith D, Karnieli E. The metabolic syndrome-from insulin resistance to obesity and diabetes. Endocrinol Metab Clin North Am. 2008; 37:559–579.

4. Romao I, Roth J. Genetic and environmental interactions in obesity and type 2 diabetes. J Am Diet Assoc. 2008; 108:S24–S28.

5. World Health Organization (WHO). Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Report of a WHO Consultation. Geneva: World Health Organization;1999.

6. Mabry RM, Reeves MM, Eakin EG, Owen N. Gender differences in prevalence of the metabolic syndrome in Gulf Cooperation Council Countries: a systematic review. Diabet Med. 2010; 27:593–597.

7. Beltrán-Sánchez H, Harhay MO, Harhay MM, McElligott S. Prevalence and trends of metabolic syndrome in the adult US population, 1999-2010. J Am Coll Cardiol. 2013; 62:697–703.

8. Swinburn BA, Sacks G, Hall KD, McPherson K, Finegood DT, Moodie ML, Gortmaker SL. The global obesity pandemic: shaped by global drivers and local environments. Lancet. 2011; 378:804–814.

9. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity in the United States, 2009-2010. NCHS Data Brief. 2012; 1–8.

10. Manjunath D, Uthappa CK, Kattula SR, Allam RR, Chava N, Oruganti G. Metabolic syndrome among urban Indian young adults: prevalence and associated risk factors. Metab Syndr Relat Disord. 2014; 12:381–389.

11. Ford ES, Giles WH. A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care. 2003; 26:575–581.

12. Chuengsamarn S, Rattanamongkoulgul S, Villarroel A. Association between metabolic syndrome and risk of cardiovascular disease, using different criteria and stratified by sex. Int J Diabetes Mellit. 2010; 2:78–82.

13. van Beek EA, Bakker AH, Kruyt PM, Hofker MH, Saris WH, Keijer J. Intra- and interindividual variation in gene expression in human adipose tissue. Pflugers Arch. 2007; 453:851–861.

14. Kelesidis T, Kelesidis I, Chou S, Mantzoros CS. Narrative review: the role of leptin in human physiology: emerging clinical applications. Ann Intern Med. 2010; 152:93–100.

15. Özçelik E, Uslu S, Kebapçı N, Kara M, Dokumacıoğlu A, Musmul A. Interrelations of serum leptin levels with adrenocorticotropic hormone, basal cortisol and dehydroepiandrosterone sulphate levels in patients with metabolic syndrome. Diabetes Metab Syndr. 2010; 4:13–17.

16. Yun JE, Kimm H, Jo J, Jee SH. Serum leptin is associated with metabolic syndrome in obese and nonobese Korean populations. Metabolism. 2010; 59:424–429.

17. Björntorp P. Hypertension and the Metabolic Syndrome: closely related central origin? Int Congr Ser. 2002; 1241:81–86.

18. Ukkola O, Kesäniemi YA. Leptin and high-sensitivity C-reactive protein and their interaction in the metabolic syndrome in middle-aged subjects. Metabolism. 2007; 56:1221–1227.

19. Martin SS, Qasim A, Reilly MP. Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease. J Am Coll Cardiol. 2008; 52:1201–1210.

20. Thorand B, Zierer A, Baumert J, Meisinger C, Herder C, Koenig W. Associations between leptin and the leptin / adiponectin ratio and incident Type 2 diabetes in middle-aged men and women: results from the MONICA / KORA Augsburg study 1984-2002. Diabet Med. 2010; 27:1004–1011.

21. Wallace AM, McMahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A, Sattar N. WOSCOPS Executive Committee. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation. 2001; 104:3052–3056.

22. Li WC, Hsiao KY, Chen IC, Chang YC, Wang SH, Wu KH. Serum leptin is associated with cardiometabolic risk and predicts metabolic syndrome in Taiwanese adults. Cardiovasc Diabetol. 2011; 10:36–42.

23. Ingelsson E, Larson MG, Yin X, Wang TJ, Meigs JB, Lipinska I, Benjamin EJ, Keaney JF Jr, Vasan RS. Circulating ghrelin, leptin, and soluble leptin receptor concentrations and cardiometabolic risk factors in a community-based sample. J Clin Endocrinol Metab. 2008; 93:3149–3157.

24. Numata T, Miyatake N, Wada J, Makino H. Comparison of serum uric acid levels between Japanese with and without metabolic syndrome. Diabetes Res Clin Pract. 2008; 80:e1–e5.

25. de Oliveira EP, Burini RC. High plasma uric acid concentration: causes and consequences. Diabetol Metab Syndr. 2012; 4:12–19.

26. Nakagawa T, Hu H, Zharikov S, Tuttle KR, Short RA, Glushakova O, Ouyang X, Feig DI, Block ER, Herrera-Acosta J, Patel JM, Johnson RJ. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol. 2006; 290:F625–F631.

27. Lee MS, Lin SC, Chang HY, Lyu LC, Tsai KS, Pan WH. High prevalence of hyperuricemia in elderly Taiwanese. Asia Pac J Clin Nutr. 2005; 14:285–292.

28. Ford ES, Li C, Cook S, Choi HK. Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents. Circulation. 2007; 115:2526–2532.

29. Sui X, Church TS, Meriwether RA, Lobelo F, Blair SN. Uric acid and the development of metabolic syndrome in women and men. Metabolism. 2008; 57:845–852.

30. Chiou WK, Wang MH, Huang DH, Chiu HT, Lee YJ, Lin JD. The relationship between serum uric acid level and metabolic syndrome: differences by sex and age in Taiwanese. J Epidemiol. 2010; 20:219–224.

31. Liu M, He Y, Jiang B, Wu L, Yang S, Wang Y, Li X. Association between serum uric acid level and metabolic syndrome and its sex difference in a chinese community elderly population. Int J Endocrinol. 2014; 754678.

32. Billiet L, Doaty S, Katz JD, Velasquez MT. Review of hyperuricemia as new marker for metabolic syndrome. ISRN Rheumatol. 2014; 852954.

33. Sheikhbahaei S, Fotouhi A, Hafezi-Nejad N, Nakhjavani M, Esteghamati A. Serum uric acid, the metabolic syndrome, and the risk of chronic kidney disease in patients with type 2 diabetes. Metab Syndr Relat Disord. 2014; 12:102–109.

34. Lin JD, Chiou WK, Chang HY, Liu FH, Weng HF. Serum uric acid and leptin levels in metabolic syndrome: a quandary over the role of uric acid. Metabolism. 2007; 56:751–756.

35. Liu PW, Chang TY, Chen JD. Serum uric acid and metabolic syndrome in Taiwanese adults. Metabolism. 2010; 59:802–807.

36. Longo-Mbenza B, Mvindu HN, Phanzu BK, OnKin JB, Nkakudulu Bikuku H, Nge Okwe A. Is uric acid a surrogate and additional component of incident metabolic syndrome, insulin resistance among inactive Central Africans? Diabetes Metab Syndr. 2010; 4:74–81.

37. Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract. 2014; 943162.

38. Obeidat AA, Ahmad MN, Haddad FH, Azzeh FS. Evaluation of several anthropometric indices of obesity as predictors of metabolic syndrome in Jordanian adults. Nutr Hosp. 2015; 32:667–677.

39. Ajlouni K, Jaddou H, Batieha A. Diabetes and impaired glucose tolerance in Jordan: prevalence and associated risk factors. J Intern Med. 1998; 244:317–323.

40. Centers for Disease Control and Prevention (CDC). Prevalence of selected risk factors for chronic disease--Jordan, 2002. MMWR Morb Mortal Wkly Rep. 2003; 52:1042–1044.

41. Centers for Disease Control and Prevention (CDC). Assessing risk factors for chronic disease--Jordan, 2004. MMWR Morb Mortal Wkly Rep. 2006; 55:653–655.

42. Hammoudeh AJ, Al-Tarawneh H, Elharassis A, Haddad J, Mahadeen Z, Badran N, Izraiq M, Al-Mousa E. Prevalence of conventional risk factors in Jordanians with coronary heart disease: the Jordan Hyperlipidemia and Related Targets Study (JoHARTS). Int J Cardiol. 2006; 110:179–183.

43. Khader Y, Bateiha A, El-Khateeb M, Al-Shaikh A, Ajlouni K. High prevalence of the metabolic syndrome among Northern Jordanians. J Diabetes Complications. 2007; 21:214–219.

44. Al-Odat AZ, Ahmad MN, Haddad FH. References of anthropometric indices of central obesity and metabolic syndrome in Jordanian men and women. Diabetes Metab Syndr. 2012; 6:15–21.

45. Obeidat BA, Al-Shami EK, Abdul-Razzak KK, Khader YS. Predictors of metabolic syndrome among employees: a study from Jordan. Food Nutr Sci. 2012; 3:669–677.

46. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome [Internet]. Brussels: International Diabetes Federation Communications;2006. 03. 19. cited 2014 October 11. Available from: http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf.

47. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey: anthropometry and physical activity monitor procedures manual [Internet]. Atlanta (GA): Centers for Disease Control and Prevention;2005. 01. 01. cited 2014 October 11. http://www.cdc.gov/nchs/data/nhanes/nhanes_05_06/BM.pdf.

48. Lee RD, Nieman DC. Nutritional Assessment. 5th ed. New York (NY): McGraw-Hill Education;2010.

49. Chen H, Sullivan G, Quon MJ. Assessing the predictive accuracy of QUICKI as a surrogate index for insulin sensitivity using a calibration model. Diabetes. 2005; 54:1914–1925.

50. Akobeng AK. Understanding diagnostic tests 3: receiver operating characteristic curves. Acta Paediatr. 2007; 96:644–647.

51. Canatan H, Bakan I, Akbulut M, Baydas G, Halifeoglu I, Gursu MF. Comparative analysis of plasma leptin levels in both genders of patients with essential hypertension and healthy subjects. Endocr Res. 2004; 30:95–105.

52. Lyoussi B, Ragala MA, Mguil M, Chraibi A, Israili ZH. Gender-specific leptinemia and its relationship with some components of the metabolic syndrome in Moroccans. Clin Exp Hypertens. 2005; 27:377–394.

53. Hamed M, Haddad SH, AL Quobili F. Serum uric acid and leptin levels in metabolic syndrome. Int J Pharm Sci Rev Res. 2013; 20:21–27.

54. Correia ML, Haynes WG. Obesity-related hypertension: is there a role for selective leptin resistance? Curr Hypertens Rep. 2004; 6:230–235.

55. Lee CY, Lee CH, Tsai S, Huang CT, Wu MT, Tai SY, Lin FF, Chao NC, Chang CJ. Association between serum leptin and adiponectin levels with risk of insulin resistance and impaired glucose tolerance in non-diabetic women. Kaohsiung J Med Sci. 2009; 25:116–125.

56. Zhuo Q, Wang Z, Fu P, Piao J, Tian Y, Xu J, Yang X. Comparison of adiponectin, leptin and leptin to adiponectin ratio as diagnostic marker for metabolic syndrome in older adults of Chinese major cities. Diabetes Res Clin Pract. 2009; 84:27–33.

57. Chien KL, Hsu HC, Sung FC, Su TC, Chen MF, Lee YT. Hyperuricemia as a risk factor on cardiovascular events in Taiwan: The Chin-Shan Community Cardiovascular Cohort Study. Atherosclerosis. 2005; 183:147–155.

58. Milionis HJ, Kakafika AI, Tsouli SG, Athyros VG, Bairaktari ET, Seferiadis KI, Elisaf MS. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Am Heart J. 2004; 148:635–640.

59. Solymoss BC, Bourassa MG, Campeau L, Sniderman A, Marcil M, Lespérance J, Lévesque S, Varga S. Effect of increasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease angiographic severity. Am J Cardiol. 2004; 93:159–164.

60. Yoo TW, Sung KC, Shin HS, Kim BJ, Kim BS, Kang JH, Lee MH, Park JR, Kim H, Rhee EJ, Lee WY, Kim SW, Ryu SH, Keum DG. Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ J. 2005; 69:928–933.

61. Ishizaka N, Ishizaka Y, Toda E, Nagai R, Yamakado M. Association between serum uric acid, metabolic syndrome, and carotid atherosclerosis in Japanese individuals. Arterioscler Thromb Vasc Biol. 2005; 25:1038–1044.

62. Rho YH, Woo JH, Choi SJ, Lee YH, Ji JD, Song GG. Association between serum uric acid and the Adult Treatment Panel III-defined metabolic syndrome: results from a single hospital database. Metabolism. 2008; 57:71–76.